{"product_id":"cadonilimab","title":"Cadonilimab","description":"\u003cp\u003eCadonilimab is a bispecific antibody that targets the PD-1 and CTLA-4 receptors on tumor cells to treat various solid cancers. In June 2022, cadonilimab was approved in China for use in patients with relapsed or metastatic cervical cancer.\u003c\/p\u003e\u003cul\u003e\u003cli\u003e\n\u003cspan data-huuid=\"5813577302449632437\"\u003eCadonilimab \u003c\/span\u003esold under the brand name 开坦尼® in china.\u003c\/li\u003e\u003c\/ul\u003e","brand":"Akeso, Inc, China","offers":[{"title":"Default Title","offer_id":44797956816939,"sku":"RL3220250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-01-0837.jpg?v=1787022270","url":"https:\/\/xomeds.com\/products\/cadonilimab","provider":"XOMEDS","version":"1.0","type":"link"}